CERo Therapeutics Financials

CERO Stock   0.07  0.01  8.42%   
Based on the key indicators related to CERo Therapeutics' liquidity, profitability, solvency, and operating efficiency, CERo Therapeutics Holdings, may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. Key indicators impacting CERo Therapeutics' financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio1.571.6547
Notably Down
Slightly volatile
Investors should never underestimate CERo Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor CERo Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in CERo Therapeutics Holdings,.

Net Income

(2,663.04)

  
Understanding current and past CERo Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of CERo Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in CERo Therapeutics' assets may result in an increase in income on the income statement.

CERo Therapeutics Stock Summary

CERo Therapeutics competes with CarsalesCom, Akanda Corp, Catalent, Xunlei, and WT Offshore. CERo Therapeutics is entity of United States. It is traded as Stock on NASDAQ exchange.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
CUSIP71902K105
Older SymbolPBAX
LocationCalifornia; U.S.A
Business Address201 Haskins Way,
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.cero.bio
Phone215 731 9450

CERo Therapeutics Key Financial Ratios

CERo Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining CERo Therapeutics's current stock value. Our valuation model uses many indicators to compare CERo Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across CERo Therapeutics competition to find correlations between indicators driving CERo Therapeutics's intrinsic value. More Info.
CERo Therapeutics Holdings, is number one stock in return on asset category among its peers. It also is the top company in current valuation category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the CERo Therapeutics' earnings, one of the primary drivers of an investment's value.

CERo Therapeutics Systematic Risk

CERo Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. CERo Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fifty-two with a total number of output elements of nine. The Beta measures systematic risk based on how returns on CERo Therapeutics correlated with the market. If Beta is less than 0 CERo Therapeutics generally moves in the opposite direction as compared to the market. If CERo Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one CERo Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of CERo Therapeutics is generally in the same direction as the market. If Beta > 1 CERo Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.

CERo Therapeutics December 13, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of CERo Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of CERo Therapeutics Holdings,. We use our internally-developed statistical techniques to arrive at the intrinsic value of CERo Therapeutics Holdings, based on widely used predictive technical indicators. In general, we focus on analyzing CERo Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build CERo Therapeutics's daily price indicators and compare them against related drivers.
When determining whether CERo Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CERo Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cero Therapeutics Holdings, Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cero Therapeutics Holdings, Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CERo Therapeutics Holdings,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CERo Therapeutics. If investors know CERo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CERo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.19)
Return On Assets
(0.45)
The market value of CERo Therapeutics is measured differently than its book value, which is the value of CERo that is recorded on the company's balance sheet. Investors also form their own opinion of CERo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CERo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CERo Therapeutics' market value can be influenced by many factors that don't directly affect CERo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CERo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CERo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CERo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.